Nautilus Biotechnology, Inc. (NAUT)Healthcare | Biotechnology | Seattle, United States | NasdaqCM
0.89 USD
-0.02
(-2.035%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.90 +0.01 (1.615%) ⇧ (Aug. 28, 2026, 7:35 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:48 a.m. EDT
The investment case for Nautilus Biotechnology is currently broken by a catastrophic multi-year decline and deteriorating fundamentals. Over the last five years, the stock has lost over 93% of its value, driven by four consecutive years of negative annual returns. The business is bleeding cash, with operating margins collapsing to nearly -83% and free cash flow turning sharply negative. While the balance sheet shows a high current ratio due to minimal debt, the company is burning through its cash reserves without generating revenue or profitability. The market has correctly priced this as a deep value trap; a low price-to-book ratio here reflects the reality of a failing operation, not a bargain. With no dividend to provide income and a statistical forecast predicting further downside despite its very low reliability, the outlook remains bleak. The options market confirms this pessimism, with traders buying deep out-of-the-money puts to hedge against further drops while ignoring any potential for a rally. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.540592 |
| AutoARIMA | 0.594244 |
| AutoETS | 0.597349 |
| MSTL | 0.612246 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 13.86 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.035 |
| Excess Kurtosis | -1.88 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 21.215 |
| Revenue per Share | 0.002 |
| Market Cap | 112,553,744 |
| Forward P/E | -1.20 |
| Beta | 0.87 |
| Website | https://www.nautilus.bio |
As of Aug. 22, 2026, 5:48 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Call activity is negligible and entirely out-of-the-money, indicating zero speculative demand for rallies. Conversely, put volume is concentrated in the December 2026 expiration, with significant open interest at strikes far above the current price (2.5 and 5.0), suggesting a strong consensus expectation of further significant declines before year-end.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.31649327 |
| Address1 | 2,701 Eastlake Avenue East |
| All Time High | 25.886 |
| All Time Low | 0.62 |
| Ask | 1.14 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 579,710 |
| Average Daily Volume3 Month | 859,492 |
| Average Volume | 859,492 |
| Average Volume10Days | 579,710 |
| Beta | 0.871 |
| Bid | 0.6329 |
| Bid Size | 2 |
| Book Value | 1.031 |
| City | Seattle |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.8857 |
| Current Ratio | 10.143 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.9177 |
| Day Low | 0.8722 |
| Debt To Equity | 21.215 |
| Display Name | Nautilus Biotechnology |
| Earnings Call Timestamp End | 1,785,241,800 |
| Earnings Call Timestamp Start | 1,785,241,800 |
| Earnings Timestamp | 1,785,241,800 |
| Earnings Timestamp End | 1,793,104,200 |
| Earnings Timestamp Start | 1,793,104,200 |
| Ebitda | -61,346,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.921 |
| Enterprise To Revenue | 297.342 |
| Enterprise Value | 56,494,952 |
| Eps Forward | -0.74 |
| Eps Trailing Twelve Months | -0.44 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.41982 |
| Fifty Day Average Change | -0.53411996 |
| Fifty Day Average Change Percent | -0.37618852 |
| Fifty Two Week Change Percent | 31.649326 |
| Fifty Two Week High | 4.31 |
| Fifty Two Week High Change | -3.4243 |
| Fifty Two Week High Change Percent | -0.7945012 |
| Fifty Two Week Low | 0.62 |
| Fifty Two Week Low Change | 0.26569998 |
| Fifty Two Week Low Change Percent | 0.42854837 |
| Fifty Two Week Range | 0.62 - 4.31 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,596,807,000,000 |
| Float Shares | 58,402,512 |
| Forward Eps | -0.74 |
| Forward P E | -1.1968919 |
| Free Cashflow | -29,418,376 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 127 |
| Fullday Change | -0.0184 |
| Fullday Change Percent | -2.03517 |
| Fullday Price | 0.9 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.92105 |
| Gross Profits | 175,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.32015 |
| Held Percent Institutions | 0.45231998 |
| Implied Shares Outstanding | 127,078,855 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington. |
| Long Name | Nautilus Biotechnology, Inc. |
| Market | us_market |
| Market Cap | 112,553,744 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_568970644 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -56,521,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 115,051,447 |
| Number Of Analyst Opinions | 1 |
| Open | 0.9 |
| Operating Cashflow | -50,235,000 |
| Operating Margins | -82.963165 |
| Payout Ratio | 0.0 |
| Phone | 206 333 2001 |
| Post Market Change | 0.014299989 |
| Post Market Change Percent | 1.6145409 |
| Post Market Price | 0.9 |
| Post Market Time | 1,787,960,104 |
| Previous Close | 0.9041 |
| Price Hint | 4 |
| Price To Book | 0.8590688 |
| Price To Sales Trailing12 Months | 592.3881 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.727 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0184 |
| Regular Market Change Percent | -2.03517 |
| Regular Market Day High | 0.9177 |
| Regular Market Day Low | 0.8722 |
| Regular Market Day Range | 0.8722 - 0.9177 |
| Regular Market Open | 0.9 |
| Regular Market Previous Close | 0.9041 |
| Regular Market Price | 0.8857 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 484,066 |
| Return On Assets | -0.2083 |
| Return On Equity | -0.36208 |
| Revenue Per Share | 0.002 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 127,078,855 |
| Shares Percent Shares Out | 0.0248 |
| Shares Short | 3,154,786 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,448,757 |
| Short Name | Nautilus Biotechnology, Inc. |
| Short Percent Of Float | 0.0504 |
| Short Ratio | 3.8 |
| Source Interval | 15 |
| State | WA |
| Symbol | NAUT |
| Target High Price | 4.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.0 |
| Target Median Price | 4.0 |
| Total Cash | 84,031,000 |
| Total Cash Per Share | 0.66 |
| Total Debt | 27,816,000 |
| Total Revenue | 190,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.18658 |
| Two Hundred Day Average Change | -1.30088 |
| Two Hundred Day Average Change Percent | -0.5949382 |
| Type Disp | Equity |
| Volume | 484,066 |
| Website | https://www.nautilus.bio |
| Zip | 98,102 |